Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05169177Recruiting

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

Role: collaborator

NCT05184790Recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Role: collaborator

NCT01418040Completed

PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)

Role: lead

NCT00193856Phase 3Completed

RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Role: collaborator

All 4 trials loaded